CONJUPRI Drug Patent Profile

Which patents cover Conjupri, and when can generic versions of Conjupri launch?

Conjupri is a drug marketed by Cspc Ouyi and is included in one NDA.

The generic ingredient in CONJUPRI is levamlodipine maleate. One supplier is listed for this compound. Additional details are available on the levamlodipine maleate profile page.

Summary for CONJUPRI

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	14
What excipients (inactive ingredients) are in CONJUPRI?	CONJUPRI excipients list
DailyMed Link:	CONJUPRI at DailyMed

US Patents and Regulatory Information for CONJUPRI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cspc Ouyi	CONJUPRI	levamlodipine maleate	TABLET;ORAL	212895-001	Dec 19, 2019		DISCN	Yes	No
Cspc Ouyi	CONJUPRI	levamlodipine maleate	TABLET;ORAL	212895-002	Dec 19, 2019		DISCN	Yes	No
Cspc Ouyi	CONJUPRI	levamlodipine maleate	TABLET;ORAL	212895-003	Dec 19, 2019		DISCN	Yes	No

Last updated: July 26, 2026

Conjupri market dynamics and financial trajectory (pricing, demand drivers, competition, and exclusivity risk)

Conjupri (verapamil hydrochloride) has limited publicly trackable U.S. revenue data because it is marketed as a brand product in a mature cardiovascular class and appears to face generic pressure over time. The market’s near-term trajectory is driven by (1) background demand for verapamil therapy in hypertension, angina, and arrhythmia management, (2) payer and procurement preferences shifting toward lowest-net-cost generics and authorized generics, and (3) the persistence or removal of brand-specific patent or exclusivity barriers. Commercial outcomes typically track net pricing erosion, volume stability in specific prescriber pockets, and formulary position rather than step-change clinical uptake.

The strongest economic reality for Conjupri is that verapamil is a long-established small-molecule, and brand differentiation in most markets is constrained to dosage form, release profile, labeling, and manufacturing scale. Over time, those advantages compress as equivalent generic products proliferate and PBM policies tighten.

---

What is Conjupri and how does it fit into the verapamil market?

Conjupri is a verapamil hydrochloride product used in cardiovascular indications aligned with verapamil’s pharmacology (calcium channel blockade). In practice, the product competes within the oral and dose-form specific segments for verapamil (including immediate-release and extended-release where applicable), alongside other calcium channel blockers (dihydropyridines like amlodipine) that often capture formulary share depending on comorbidity profiles.

Key competitive adjacency

• Other oral calcium channel blockers: amlodipine, diltiazem
• Generic verapamil manufacturers and authorized generics
• Therapeutic substitution risk: where dihydropyridines are preferred for hypertension, and diltiazem is preferred in rate control or angina pathways

Where Conjupri wins commercially

• If Conjupri has a formulary-specific position versus immediate-release vs extended-release equivalents
• If the product is entrenched with particular prescribers who prefer its release profile or tolerability profile
• If payers treat it as a preferred option within a narrow segment before generic switches

Where Conjupri loses commercially

• Net price erosion driven by generic equivalence
• Plan design (tier placement, prior authorization, step edits) that accelerates switches
• Competition from higher-volume manufacturers with strong wholesaler distribution and rebate economics

---

How do pricing and net revenue trends typically evolve for branded verapamil products like Conjupri?

Featured by payer behavior and market structure, brand net revenue in mature small-molecule cardiovascular classes usually follows a predictable pattern:

1. High gross-to-net discounts while brand differentiation remains stable
2. Tier migration and increasing rebate pressure
3. Switch to lowest-cost generics
4. Residual brand survival if patents, exclusivity, or formulation barriers delay full generic saturation

Commercial levers that shape Conjupri’s financial trajectory

• List price setting vs realized net price (rebates, chargebacks, wholesaler terms)
• Formulary placement (preferred vs non-preferred)
• Medicaid and Medicare Part D contract dynamics (regional and plan-level)
• Distributor buy-down behavior during generic launches
• Persistence and adherence in chronic indications (volume retention even when price falls)

Revenue sensitivity

• Verapamil class demand is relatively steady, so the main financial swing is typically net price, not catastrophic demand collapse.
• The most damaging scenario for a brand is broad competitive switching across retail and PBM channels rather than a narrow segment loss.

---

When does Conjupri face exclusivity expiration and generic entry risk?

A complete exclusivity and patent-expiration timeline requires the specific Orange Book listing, listed patents, and FDA exclusivity periods for Conjupri. Without a verifiable Orange Book record and patent identifiers, the exclusivity schedule cannot be mapped precisely to calendar dates.

What can be stated as market-mechanics is that generic entry risk rises sharply once:

• Any listed brand-use patents expire or are carved out by scope/expiration
• Manufacturing-process or formulation patents are invalidated or settle under consent judgments
• Exclusivity protections (if any beyond basic regulatory exclusivity) end, enabling paragraph IV and non-paragraph IV generic pathways to land competitively

For mature drugs like verapamil, the economic question is usually not whether generic entry occurs, but when full retail channel switching occurs and whether brand pricing can stabilize long enough to retain cash-flow.

---

What Orange Book status would drive Conjupri’s financial outlook?

The Orange Book status is the market’s “switch point” for commercial forecasting:

• If Conjupri has active listed patents that delay ANDA approvals, branded sales can hold longer due to slower generic availability.
• If Conjupri’s listed patents are expired, sales shift toward a generic-dominant equilibrium quickly as PBMs implement automatic formulary switches.

What to monitor in Orange Book terms

• Patent number coverage categories (drug substance, drug product, method of use)
• Whether patents are “Orange Book listed” and aligned with the specific NDC(s)
• Whether any 30-month stay events occurred historically in litigation

Without Conjupri’s NDC-specific Orange Book record and patent identifiers, the status cannot be stated with the precision required for litigation or investment-grade timing.

---

What patents protect Conjupri and how strong is the patent estate?

For a verapamil brand product, the patent estate strength depends on whether protection is anchored in:

• Method-of-use claims unique to branded labeling
• Specific formulation and release technologies (extended-release coatings, bead systems, controlled porosity)
• Manufacturing process claims with enforceable scope

In a typical mature cardiovascular brand, the strongest estate components are formulation and process patents that prevent “work-around” manufacturing. If those are missing or have expired, the estate weakens rapidly to enforcement only against non-infringing generic design choices, which often fails to slow market switching.

A defensible assessment requires Conjupri’s listed patents and their expiration dates by number, jurisdiction, and assignee. Those inputs are not provided here, so a strength ranking cannot be constructed for Conjupri specifically.

---

Have there been Paragraph IV challenges or patent litigations that impacted Conjupri’s market share?

Paragraph IV challenges drive:

• 30-month stays that delay generic launch
• Settlement terms that cap generic timelines or create “authorized generic” carve-outs
• Market-share recovery or continued decline based on litigation outcomes

A precise answer requires docket-level litigation data tied to Conjupri’s Orange Book patents and ANDA filers. That is not available in the prompt, so the litigation impact cannot be quantified.

---

How does Conjupri compare with competing calcium channel blockers (amlodipine and diltiazem) in market dynamics?

Substitution pressure

• Hypertension: dihydropyridine calcium channel blockers, especially amlodipine, often capture first-line payer preferences because of dosing convenience and tolerability profiles.
• Angina: both verapamil and diltiazem have roles; choice depends on comorbidity and prescriber preference.
• Rate control and arrhythmia: diltiazem frequently competes in the same clinical decision space.

Commercial implication

If payer formularies shift toward amlodipine or diltiazem as preferred options, Conjupri’s unit demand becomes more dependent on physician inertia and patient-specific fit rather than class-level growth.

---

What distribution and channel dynamics matter most for Conjupri financial trajectory?

For chronic cardiovascular generics and brands:

• Retail persistence drives revenue more than new patient conversion
• Wholesaler inventory management and contract terms can create short-term fluctuations around generic launches
• PBM rebate negotiation and contracting cycles determine realized net pricing

Channel profile (typical pattern)

• Start: brand premium with stronger physician acceptance
• Mid: generic infiltration begins; brand negotiates deeper rebates
• Later: brand becomes a niche SKU unless protected by enforceable patent/formulation barriers

---

What manufacturing and supply chain factors can move Conjupri sales?

Supply constraints can temporarily protect a brand’s net price and volume, but for established verapamil products, supply risk is usually less material than:

• Availability of competing generics
• Contracting and rebate economics
• Formulary controls

If Conjupri’s specific dosage form depends on proprietary manufacturing, shortages may happen during tech transfer or process scale-up changes. Without NDC-level manufacturing site disclosures and inspection history, the effect cannot be mapped to a specific financial timeline.

---

How likely is biosimilar or biologics-style disruption for Conjupri?

Conjupri is a small-molecule verapamil product, not a biologic. Biosimilar disruption is not applicable. Competition is instead governed by ANDAs, generics, and possible authorized generic programs, plus any formulation or method-of-use patent barriers.

---

What generic entry scenarios exist for Conjupri, and how do they affect revenue?

A generic entry scenario for a small-molecule brand typically falls into one of three patterns:

1. Full generic substitution across retail: largest volume drop; revenue follows net price erosion
2. Segmented substitution: switches in one release profile or one plan segment; brand retains residual share
3. Authorized generic overlay: rapid pricing compression without fully removing brand presence

For Conjupri, which scenario dominates depends on patent and exclusivity status by dosage form and NDC, the number and timing of ANDA approvals, and settlement outcomes. Those specifics are not provided here.

---

Key Takeaways

• Conjupri sits in a mature cardiovascular drug class where long-term financial trajectory is primarily determined by net pricing erosion and formulary switching, not clinical-driven expansion.
• Market dynamics favor generics as exclusivity and patent barriers lapse, with revenue protected only temporarily by enforceable product-specific IP or strong plan-specific positioning.
• The decisive gating item for investment-grade forecasting is Conjupri’s NDC-specific Orange Book status and the associated patent expiration and litigation history, which determines how quickly branded sales compress after generic launches.
• Competitive substitution risk from other calcium channel blockers (amlodipine, diltiazem) adds downward pressure on branded share, especially where PBMs prefer those alternatives for hypertension and related cardiovascular pathways.

---

FAQs

1) What drives Conjupri sales more: unit volume or net price?

Net price is typically the dominant driver in mature small-molecule brands; volume is comparatively stable unless formulary switches are broad.

2) Do calcium channel blocker formularies treat verapamil and amlodipine interchangeably?

Often they are alternatives within the class, but plan preferences and patient-specific factors decide which agent is placed as preferred, affecting branded verapamil share.

3) How does the timing of generic approvals affect branded Conjupri revenue?

Branded revenue usually declines most sharply around the transition from limited generic availability to broad retail contracting and PBM tier migration.

4) What would be the highest-value data point to forecast Conjupri’s future cash flow?

The NDC-linked Orange Book listing showing listed patents and expiration dates, paired with ANDA approval dates and any settlement-driven entry timing.

5) Can Conjupri face method-of-use or formulation-specific generic work-arounds?

Yes in principle; if a brand relies on formulation-release IP or unique method-of-use labeling, generics may design around those claims. The practical impact depends on enforceable claim scope and whether generics choose to certify against those patents.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA. Drug Approval Reports and databases (NDAs/ANDAs). https://www.accessdata.fda.gov/
3. U.S. FDA. ANDA and Paragraph IV framework overview (legal/regulatory pathway context). https://www.fda.gov/